SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
April 20, 2021 07:00 ET
|
SparingVision
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis...
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
April 20, 2021 01:00 ET
|
SparingVision
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
March 19, 2021 08:00 ET
|
SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
March 19, 2021 02:00 ET
|
SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
SparingVision Conference Participation in H1 2021
February 16, 2021 07:00 ET
|
SparingVision
SparingVision Conference Participation in H1 2021 Paris, February 16, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases,...
SparingVision Conference Participation in H1 2021
February 16, 2021 01:00 ET
|
SparingVision
SparingVision Conference Participation in H1 2021 Paris, February 16, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases,...
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
February 04, 2021 01:00 ET
|
SparingVision
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of...
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
February 04, 2021 01:00 ET
|
SparingVision
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
January 29, 2021 07:00 ET
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
January 29, 2021 01:00 ET
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...